Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

2913 - Improving outcomes in triple-negative breast cancer (TNBC) using molecular characterization and diagnostic imaging to identify and treat chemo-insensitive disease


10 Oct 2016


Poster display


Stacy Moulder


Annals of Oncology (2016) 27 (6): 43-67. 10.1093/annonc/mdw364


S.L. Moulder1, J.K. Litton1, E. Mittendorf2, W. Yang3, N. Ueno4, K.R. Hess5, V. Valero4, R.K. Murthy1, N. Ibrahim1, B. Lim1, B.K. Arun1, A. Thompson2, H. Piwnica-Worms6, D. Tripathy7, W.F. Symmans8

Author affiliations

  • 1 Breast Medical Oncology, MD Anderson Cancer Center, 77030 - Houston/US
  • 2 Department Of Surgery, MD Anderson Cancer Center, Houston/US
  • 3 Diagnostic Imaging, MD Anderson Cancer Center, Houston/US
  • 4 Breast Medical Oncology, MD Anderson Cancer Center, Houston/US
  • 5 Biostatistics, MD Anderson Cancer Center, 77030 - Houston/US
  • 6 Vice Provost Of Science, MD Anderson Cancer Center, 77030 - Houston/US
  • 7 Department Of Breast Medical Oncology, MD Anderson Cancer Center, 77030-4095 - Houston/US
  • 8 Molecular Diagnostics, MD Anderson Cancer Center, Houston/US


Abstract 2913


TNBC treated using neoadjuvant chemotherapy (NACT) has a varied prognosis with 50% of patients (pts) having excellent response to treatment (pCR/RCB-I) and excellent prognosis, while 50% have marked residual disease (RCB-II-III) and significantly worse prognosis. Lack of response to an initial NACT regimen also indicates a low chance (5%) of achieving pCR with subsequent chemotherapy, even if drugs are changed.

Trial design

This randomized study will determine the impact of predicting chemosensitivity to NACT using molecular characterization combined with diagnostic imaging and determine if offering a clinical trial of selected targeted therapy will impact outcomes (as measured by pCR and RCB) in predicted chemo-insensitive disease. The algorithm uses a pre-defined genomic signature (JAMA, 2011;305:1873-81) and response to an intitial course of anthracycline based NACT to determine predicted sensitivity to chemotherapy. Pts undergo biopsy of the primary tumor prior to NACT and are randomized 2:1 to know the molecular testing results versus not (control). For the second phase of neoadjuvant therapy, pts who fit molecular/imaging criteria for chemo-insensitive disease after AC are offered a clinical trial based upon comprehensive molecular profiling (if known) or based upon physician/patient choice if randomized to the control arm. Pts with chemo-sensitive disease continue with taxane based NACT. Success is defined as improvement in the rate of excellent pathologic response (pCR/RCB-I) from 50%– > 64% using the platform. A maximum of 360 pts will be randomized using a group sequential design with one-sided O'Brien-Fleming boundaries, with up to two equally spaced binding interim tests for both futility and superiority and one final test, having an overall Type I error .05 and power .80 to detect a response rate improvement from a null rate of .50 to a target value of .642.

Clinical trial identification

ClinicalTrials.gov Identifier: NCT02276443 (10/21/2014)

Legal entity responsible for the study

MD Anderson


MD Anderson Moon Shot Program


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings